Main Uses of Theobron

Theobron contains theophylline, a methylxanthine derivative used primarily for the long-term management of chronic respiratory conditions. It acts as a bronchodilator to alleviate symptoms associated with airflow obstruction.

Asthma

Theobron is indicated for the prevention and treatment of symptoms caused by bronchial asthma. It helps to relax the smooth muscles of the airways, reducing the frequency and severity of symptoms such as:

• Wheezing
• Shortness of breath
• Chest tightness
• Coughing

Chronic Obstructive Pulmonary Disease (COPD)

This medication is used to manage chronic bronchitis and emphysema, which are conditions under the umbrella of COPD. By maintaining open airways, it assists in improving overall lung function and exercise tolerance in patients with persistent respiratory obstruction.

Benefits and Mechanisms

Bronchodilation

The primary benefit of Theobron is its ability to relax the muscles surrounding the bronchi and bronchioles. This action increases the diameter of the airways, making it easier for air to flow into and out of the lungs.

Respiratory Muscle Support

Theophylline has been observed to strengthen the contraction of the diaphragm. This effect can be particularly beneficial for patients with chronic lung disease, as it reduces respiratory fatigue and assists in the physical process of breathing.

Clearance of Secretions

The medication may improve mucociliary clearance, which is the body's natural process for moving mucus and trapped particles out of the respiratory tract. By facilitating this process, it helps to keep the airways clear.

Regulatory References

1. NIH MedlinePlus overview of Theophylline

Eligibility Map: Who can and cannot use Theobron (Theophylline) — Official Regulatory Information

This section details the official population eligibility and non-eligibility information for Theobron (Theophylline) as documented in government regulatory sources.

Contraindications (Must Not Use)

• Hypersensitivity: Individuals with a known allergy to theophylline or any other xanthine derivative (e.g., caffeine, theobromine).
• Specific Comorbidities: Use is generally contraindicated in patients with severe, active liver disease or certain concomitant drug therapies, such as riociguat.

Populations Requiring Caution and Monitoring

Use of Theobron is permitted but requires dose adjustment and close medical supervision in patients with specific underlying conditions or physiological states due to altered drug metabolism or increased risk of toxicity:

• Organ Impairment: Patients with severe hepatic impairment (liver disease) or congestive heart failure (CHF), as the body clears the drug much slower.
• Vulnerable Conditions: Patients with active peptic ulcer disease, seizure disorders, or certain cardiac arrhythmias (excluding bradyarrhythmias), as the drug may worsen these conditions.
• Age and State: Infants under one year and elderly patients (ge 60 years) due to highly variable or decreased clearance. Pregnant and breastfeeding women must only use it if the benefit clearly outweighs the potential risk to the fetus or nursing infant.

Due to Theobron's classification as a Narrow Therapeutic Index (NTI) drug, blood monitoring is frequently required for safe use in these conditional populations.

Theobron’s interaction profile is primarily defined by pharmacokinetic changes in its systemic exposure and specific pharmacodynamic effects. Official regulatory documents list Riociguat and Viloxazine as combinations that are strongly not recommended for co-administration. Co-administration of Ephedrine is formally contraindicated in specified pediatric populations.

The most significant interactions are pharmacokinetic, resulting from altered clearance via the hepatic cytochrome P450 enzyme system. Medicines such as Ciprofloxacin and Cimetidine inhibit this metabolism, reducing Theobron clearance and potentially increasing plasma concentrations. Conversely, inducers like Rifampicin, Phenytoin, and Carbamazepine increase clearance, which may reduce systemic exposure.

Pharmacodynamic interactions are also documented; for instance, co-administration with beta-adrenergic agonists can potentiate effects, and combining Theobron with Halothane may lead to the occurrence of arrhythmias. Non-medicinal substances also impact clearance. Smoking tobacco significantly increases Theobron clearance, while smoking cessation reverses this effect. Consumption of caffeine-containing foods may increase the risk of caffeine-like side effects. An administration constraint requires that enteral tube feedings be interrupted for one hour before and one hour after the dose to mitigate absorption interference. Interaction caution is also noted for patients with hepatic impairment and elderly patients due to potentially reduced clearance.

The mechanism of action for Theobron originates from its active moiety, Theophylline, which acts through three primary and concurrent domains to modulate the signaling and functional state of cells in the airways.

**Enzyme Inhibition

ightarrow Bronchial Smooth Muscle Relaxation**

This core mechanism involves the non-selective inhibition of Phosphodiesterase (PDE) enzymes, particularly PDE3. This inhibition prevents the breakdown of the signaling molecule cAMP, which elevates its levels inside muscle cells and initiates a cascade leading directly to the relaxation of the bronchial smooth muscle tissue and increased diaphragmatic contractility.

**Receptor Antagonism

ightarrow Antagonism of Pro-Constrictive Signaling Pathways**

The drug also functions as a non-selective competitive antagonist at Adenosine Receptors (e.g., A2B), which are widely distributed throughout the body. By blocking these receptors, the mechanism opposes the natural pro-constrictive and mediator-releasing signals normally activated by endogenous Adenosine, influencing the baseline tension of the airway smooth muscle and modulation of airway hyperresponsiveness mechanisms.

**Cellular Modulation

ightarrow Suppression of Inflammatory Signaling**

At a molecular level, Theophylline enhances the activity of the nuclear enzyme Histone Deacetylase 2 (HDAC2). This action engages the cellular machinery required to suppress the transcription of genes responsible for creating pro-inflammatory mediators, resulting in the modulation of chronic inflammatory signaling within the airways.

Administration and Usage Protocol

Theobron (Choline Theophyllinate) is administered by the oral route, available in standard (immediate) release and extended-release tablet forms for long-term use. The administration protocol emphasizes consistency and frequent monitoring rather than fixed, universal guidelines for all patients.

Dosing and Scheduling

Dosing is highly individualized and is guided by the measurement of serum theophylline concentrations, with a target therapeutic range typically between 10 and 15 mug/mL to ensure proper use. For chronic treatment, the usual adult maintenance range is 400 mg to 600 mg daily (expressed as theophylline equivalent), which is typically taken in divided doses. Extended-release forms are commonly taken once or twice daily, and the medication must be taken at the same time each day to maintain steady levels. If a dose is missed, patients are instructed to take the next dose at the regularly scheduled time without doubling the amount.

Specific Procedural Conditions

The extended-release tablets must be swallowed whole; they are strictly not to be broken, cut, or chewed, as this risks a rapid, uncontrolled release of the entire dose. Dosing adjustments must be made at intervals of no less than three days to allow drug concentration to stabilize before subsequent measurement. Lower total daily doses are often required for older adults and for individuals with hepatic impairment, necessitating careful and frequent monitoring of blood levels. The treatment is designed for long-term management of chronic respiratory conditions.

The research evidence for Theobron (Choline Theophyllinate) comes from studies that have investigated its place in the evidence base for chronic obstructive airway diseases, including Chronic Obstructive Pulmonary Disease (COPD) and Chronic Asthma. This evidence primarily rests upon Randomized Controlled Trials (RCTs) and Systematic Reviews that examined the compound as a therapy for these conditions.

Researchers focused on objective and subjective outcomes. Lung function was measured using metrics like the Forced Expiratory Volume in 1 second (FEV1), and trials also monitored patient-reported symptoms such as shortness of breath and wheezing. For long-term disease management, studies explored the frequency of acute disease exacerbations over sustained periods.

In terms of findings, studies reported that measurements of lung function were collected and examined for observed patterns. However, reported patterns of change on objective measures were often described as small. Furthermore, research examining outcomes related to acute disease exacerbation frequency has sometimes produced mixed findings, meaning results are not entirely consistent across all available reports.

Clinical trials typically included study populations of Adults and Older Children. The research explores the compound's use in individuals with moderate to severe disease, including those already receiving inhaled medications. The evidence is limited in providing robust comparisons against certain other therapeutic agents, and limited information is available for long-term outcomes that track the drug's performance over many years. Researchers emphasize that findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References Theophylline - StatPearls - NCBI Bookshelf

Common questions about Theobron (FAQ)

Q: How is Theobron different from quick-relief inhalers?

Theobron is officially classified as a bronchodilator intended for the long-term management of chronic airway diseases. The active ingredient has documented actions that include relaxing airway muscles and suppressing airway responsiveness. This profile distinguishes it from medications designed specifically for immediate, acute relief of symptoms.

Q: Can Theobron affect my sleep pattern?

Official product information lists Central Nervous System (CNS) effects, such as nervousness and insomnia (difficulty sleeping), as potential adverse reactions. These reactions are primarily associated with the concentration of the medicine in the bloodstream.

Q: How does Theobron compare to other COPD or asthma tablets?

The active ingredient in Theobron is historically described in authoritative documents as a second-line bronchodilator. This means it is typically used in the management of chronic obstructive pulmonary disease (COPD) and asthma after or in combination with other primary treatments.

Q: Does Theobron interact with cold or flu medications?

Regulatory documents include a formal contraindication against co-administering the drug with Ephedrine in certain pediatric populations. Ephedrine is an ingredient found in some cold or flu medications, so patients should be aware of this documented interaction.

Q: Is Theobron considered a 'preventer' or a 'reliever' medication?

The medicine is intended for the long-term management of chronic respiratory conditions. Official documentation confirms it has non-bronchodilator prophylactic effects on the airways, meaning it is used consistently to manage and help prevent symptoms rather than for immediate relief.

Q: Can patients who have a history of heart problems use Theobron?

Regulatory documents describe that the drug’s use is subject to caution and close medical supervision in patients with a history of certain heart conditions. These conditions include cardiac arrhythmias, congestive heart failure (CHF), angina pectoris, or a history of recent myocardial infarction.

Q: Do any foods need to be avoided while taking Theobron?

The official product information notes that certain dietary factors can influence the drug's activity and absorption. This includes consuming caffeine-containing foods and, in some cases, charcoal-broiled beef. Additionally, interruption of enteral tube feedings is required around the time of the dose to avoid absorption interference.

Q: Are there different brand names for the active ingredient in Theobron?

The active ingredient in Theobron is a specific salt form of the base compound Theophylline. This base compound is used in several other medicines and is marketed under various brand names for the management of chronic airway diseases.

Q: What should a patient know about Theobron's use in combination therapies?

Theobron is classified as a prescription medicine intended to be used together with other medications as part of a comprehensive regimen to manage the symptoms of chronic obstructive airway diseases.

Q: Is Theobron ever prescribed for conditions other than lung diseases?

Official medical documents indicate that the active ingredient is used not only for chronic obstructive airway diseases but also for the treatment of apnea of prematurity in infants, which is a condition involving irregular breathing.

Q: Can certain herbal supplements or vitamins interact with Theobron?

Regulatory documents advise that the drug may interact with certain vitamins and herbal products. Official guidance emphasizes that patients should be aware of this potential for interaction.

Q: Is it required to take Theobron with food, or can it be taken on an empty stomach?

Official regulatory guidance indicates that the medicine may be taken with or without food. It is specified that a patient take the medicine the same way every time—meaning consistently—to help maintain stable concentrations in the blood.

Q: Are there long-term health effects of taking Theobron for many years?

While the medicine is designed for the long-term management of chronic respiratory conditions, official research evidence is limited regarding the tracking of the drug’s performance and outcomes over many years. This means long-term data tracking is not as complete as for some other compounds.

Q: Is Theobron considered a first-line treatment for its indicated uses?

The active ingredient in Theobron is described in authoritative documents as a second-line treatment. This means it is typically introduced after or in addition to primary therapies for chronic obstructive pulmonary disease (COPD) and asthma.

Q: Does Theobron have any known effects on kidney function or urination?

The active ingredient in the medicine is documented as having a diuretic effect, which can influence urination. For patients on prolonged therapy, official guidance may require the monitoring of fluid balance and electrolyte concentrations in the blood.

Q: Is Theobron known to interact with alcohol consumption?

Official interaction checks have documented that the active ingredient has a minor drug interaction with alcohol (ethanol).

Q: Why do doctors often prescribe Theobron when other treatments haven't fully worked?

The active ingredient in Theobron is commonly described as a second-line agent in the treatment of chronic airway diseases. This clinical positioning suggests it is often prescribed to patients when primary treatment options may need to be supplemented or adjusted.

Q: Can Theobron be used alongside blood thinners?

Official studies have specifically examined the co-administration of the active ingredient with the common blood thinner warfarin. These studies did not indicate a regulatory requirement for a dose adjustment of warfarin when the two medicines are used together.

Q: Does Theobron cause issues with stomach irritation or nausea?

Nausea and vomiting are documented as possible adverse reactions. These effects are particularly associated with the medicine when its concentration in the blood is at the higher end of the spectrum or potentially toxic.

The official storage guidelines for Theobron (Choline Theophyllinate oral tablets) emphasize environmental control and container integrity to maintain product stability.

Storage Requirements

The medication must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and protected from excessive heat and humidity. The tablets should be kept in the original container and must be tightly closed. For safety, Theobron must be stored out of the sight and reach of children and pets.

---

Disposal Instructions

Disposal of unused or expired Theobron must be handled according to local regulations. Regulatory documents instruct against discarding the medicine in wastewater or household trash unless specifically directed, supporting the use of authorized drug take-back programs.